IMRN is Immuron Limited (Healthcare) — a non-dividend-paying stock. Trading at $1.11. Market cap: $9M.
Stock snapshot
| Price | $1.11 |
| Market cap | $9M |
| Sector | Healthcare |
| Exchange | NCM |
| Pays dividend | No |
About IMRN
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
Related non-dividend companies
Other non-dividend stocks investors research alongside IMRN. Peer set from Massive news + returns similarity, filtered to names we currently track.
Frequently asked
What is IMRN's current stock price?
IMRN (Immuron Limited) is currently trading at $1.11.
Does IMRN pay a dividend?
IMRN (Immuron Limited) does not currently pay a regular dividend.
Track IMRN in DiviDrip
Add IMRN to your watchlist on DiviDrip to monitor price, fundamentals, and Capital Quality Rank week-over-week. Built for long-term investors tracking both dividend and non-dividend names.
- Open DiviDrip — search IMRN and add it to your watchlist.
- Stock Screener — filter by sector, market cap, and Capital Quality Rank.
- How to use the Screener — sector / quality / market-cap filters explained.
Data refreshed 2026-09-03. Not investment advice. Prices change continuously; always verify the latest numbers in the live app before buying.